GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.20
Bid: 5.10
Ask: 5.30
Change: 0.00 (0.00%)
Spread: 0.20 (3.922%)
Open: 5.15
High: 5.25
Low: 5.10
Prev. Close: 5.20
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Covid concerns in China drag stocks lower

Thu, 29th Dec 2022 12:14

(Alliance News) - Stock prices in London at midday continued to be weighed down by the worrying surge in Covid-19 cases as China swiftly re-opens from three years of strict lockdown measures.

"The good news with China's re-opening is that it should boost global growth. The bad news with China's reopening is that it will not only boost global growth, but also energy and commodity prices - hence inflation, the interest rate hikes from central banks and potentially the global Covid cases – which could then give birth to a new, and a dangerous Covid variant, which would, in return, bring the restrictive Covid measures back on the table, and hammer growth," said Ipek Ozkardeskaya at Swissquote Bank.

The FTSE 100 index was down 9.35 points, or 0.1%, at 7,487.84. The FTSE 250 was down 61.52 points, or 0.3% at 18,823.98, and the AIM All-Share was down 1.11 points, or 0.1%, at 831.17.

The Cboe UK 100 was down 0.2% at 748.97, the Cboe UK 250 down 0.4% at 16,295.30, and the Cboe Small Companies down 0.2% at 13,104.65.

Hospitals across China have been overwhelmed by an explosion of Covid cases following Beijing's decision to lift strict rules that had largely kept the virus at bay. 

On Monday, the country said it would bring an end to mandatory quarantine on arrival – prompting many jubilant Chinese citizens to make plans to travel abroad. In response, the US and a number of other countries announced they would require negative Covid tests for all travellers from mainland China.

Stocks in New York were called higher after Wednesday's steep sell-off. The Dow Jones Industrial Average was called up 0.2%, the S&P 500 index up 0.5%, and the Nasdaq Composite up 0.7% on Thursday. The indices closed down 1.1%, 1.2% and 1.4%, respectively, on Wednesday.

interactive investor's Victoria Scholar said continued worries about the performance of 'big tech', fears of a recession, rising interest rates, and China's complex Covid situation were weighing on Wall Street.

In London, Antofagasta fell 1.0%, after the miner reported that access to its Los Pelambres operation in Chile is being blocked by a group of people, affecting the transport of critical supplies and personnel to the mine site.

Antofagasta explained that the group is requesting compensation to clear access but added that, to date, there has been no material impact on production.

"The authorities are working to clear the blockade, and the company is engaging with them and representatives of the local communities to jointly resolve the situation," Antofagasta said.

Allergy Therapeutics plunged 52% after it said its shares will be suspended from trading next week, due to delays in completing the audit of its annual results.

Back in September, Allergy Therapeutics announced its unaudited preliminary results for the financial year that ended June 30. It sunk to a pretax loss of GBP12.7 million from a profit of GBP3.7 million the year prior. Revenue dropped to GBP72.8 million from GBP84.3 million.

"It is not aware of any material change that will be required to be made to the results, and it is actively working to finalise the audit and publication of its annual report and accounts," Allergy Therapeutics said.

Kazera Global dropped 22%. It also said its results will not be published before the end of the year, due to delays at its wholly-owned subsidiary African Tantalum.

The diamond and rare earths explorer now expects to release its results for the financial year that ended June 30 during February. As a result, its shares will be suspended from trading on AIM in London from Tuesday next week, the first trading day of 2023.

Tekcapital jumped 8.2%. It said investee Innovative Eyewear licensed outdoor brand Eddie Bauer for its smart eyewear collection through an agreement with Authentic Brands.

The company described the contract as a "multi-year, global licensing agreement", without providing financial details. The Eddie Bauer smart eyewear collection is expected to launch in 2023.

Index operator FTSE Russell revealed on Wednesday that Johnson Matthey will return to the FTSE 100 next week as part of index changes stemming from the acquisition of home repairs company Homeserve.

Johnson Matthey had been dumped from the FTSE 100 just over a year ago following an index review. Shares in the speciality chemicals firm were down 1.0% at midday on Thursday.

Early Thursday afternoon in Europe, the CAC 40 index in Paris was up 0.1%, while the DAX 40 in Frankfurt was up 0.2%.

The pound was quoted at USD1.2026 at midday on Thursday in London, down a touch compared to USD1.2029 at the close on Wednesday.

The euro stood at USD1.0633, higher against USD1.0617. Against the yen, the dollar was trading at JPY133.75, lower compared to JPY134.23.

Brent oil was quoted at USD83.00 a barrel at midday in London on Thursday, up from USD82.87 late Wednesday. Gold was quoted at USD1,806.05 an ounce, higher against USD1,801.04.

Still to come on Thursday's economic calendar, there are US weekly unemployment insurance claims at 1330 GMT.

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
6 Nov 2023 12:33

IN BRIEF: Allergy Therapeutics extends cash runway until end of 2023

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.

Read more
16 Oct 2023 08:40

ZQ makes mandatory offer for Allergy Therapeutics as holding hits 60%

(Alliance News) - ZQ Capital Management Ltd on Monday announced a mandatory takeover offer for Allergy Therapeutics PLC, as required under UK takeover rules, but it said the offer won't be accepted by the Allergy's second largest shareholder and so won't succeed.

Read more
13 Oct 2023 14:07

IN BRIEF: Allergy Therapeutics raises GBP40.8 million in fundraise

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says that it has conditionally raised total gross proceeds of approximately GBP40.8 million through an equity financing, which was announced on April 6. Proceeds of the equity financing will be used to repay amounts owed under the loan facility agreement.

Read more
27 Sep 2023 13:10

EARNINGS: Safestyle suffers amid "difficult" trading conditions

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
26 Sep 2023 19:38

TRADING UPDATES: Cohort trading ahead of expectations, record orders

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
22 Sep 2023 20:37

TRADING UPDATES: Braemar investigation to end; Marula reports delay

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday, Thursday and Wednesday and not separately reported by Alliance News:

Read more
10 Aug 2023 11:11

Allergy Therapeutics shares plunge on expected loss and revenue drop

(Alliance News) - Allergy Therapeutics PLC on Thursday said it expects to swing to a loss for the full-year as revenue plummets on production disruptions.

Read more
10 Jul 2023 13:45

Allergy Therapeutics appoints new CFO; interim CFO to leave in August

(Alliance News) - Allergy Therapeutics PLC on Monday said it has promoted Group Financial Controller Shaun Furlong to chief financial officer.

Read more
19 Jun 2023 11:40

Allergy Therapeutics banks on second half-year to boost revenue

(Alliance News) - Allergy Therapeutics PLC on Monday said its loss widened and revenue fell, with costs going up as new research studies progress, but predicted improved sales in the second half of the year thanks to higher demand in the seasonal allergy market.

Read more
6 Apr 2023 14:42

Allergy Therapeutics enters GBP41 million facility with ZQ Capital

(Alliance News) - Allergy Therapeutics PLC on Thursday said it has entered into a senior secured facility agreement with ZQ Capital Management Ltd, through its affiliate SkyGem International Holdings Ltd and Southern Fox Investments Ltd.

Read more
27 Mar 2023 18:42

TRADING UPDATES: Sabien works with Empiric; Coro sells in Italy

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
27 Mar 2023 15:16

Allergy Therapeutics starts dosing peanut allergy vaccine candidate

(Sharecast News) - Allergy Therapeutics, a UK-based biotechnology company specialising in allergy vaccines, announced the start of the first application of its 'VLP Peanut' vaccine candidate in peanut-allergic patients on Monday.

Read more
20 Jan 2023 12:33

Allergy Therapeutics confident in funding as results remain late

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said in an update on Friday that it expects first-half revenue of £39.9m, making for a decrease of 18% year-on-year.

Read more
20 Jan 2023 10:37

Allergy Therapeutics revenue drops but optimistic about funding

(Alliance News) - Allergy Therapeutics PLC on Friday said it expects a drop in revenue during the first half of its financial year, but it remains confident about funding opportunities.

Read more
29 Dec 2022 16:52

LONDON MARKET CLOSE: FTSE 100 edges higher and New York stocks jump

(Alliance News) - London's FTSE 100 achieved a solid, though unspectacular, gain during the final full trading of the year on Thursday, with investors mindful of what an ease of Covid-19 curbs in China could mean for global inflation.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.